A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Revefenacin (Primary) ; Ipratropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 22 May 2013 Pharmacokinetic results presented at the 109th International Conference of the American Thoracic Society.
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 14 Nov 2011 The full results of this study will be presented at an upcoming medical conference, according to a Theravance media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History